{"protocolSection": {"identificationModule": {"nctId": "NCT03299686", "orgStudyIdInfo": {"id": "CCJM112X2204"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma", "officialTitle": "A Randomized, Subject- and Investigator-blinded, Placebo Controlled, Multi-center, Multiple Dose Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Moderate to Severe Asthma"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-11-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-04-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-07-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-08-07", "studyFirstSubmitQcDate": "2017-09-27", "studyFirstPostDateStruct": {"date": "2017-10-03", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-07-03", "resultsFirstSubmitQcDate": "2020-07-23", "resultsFirstPostDateStruct": {"date": "2020-08-06", "type": "ACTUAL"}, "dispFirstSubmitDate": "2020-02-07", "dispFirstSubmitQcDate": "2020-07-23", "dispFirstPostDateStruct": {"date": "2020-08-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-07", "lastUpdatePostDateStruct": {"date": "2021-10-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in development for T2-high(allergic/eosinophilic) asthma. The purpose of this study was to determine if CJM112, an anti-IL-17A antibody, displayed the clinical efficacy and safety profile to support further development in patients with inadequately controlled moderate to severe asthma with low IgE and low circulating eosinophil levels.", "detailedDescription": "After an initial screening visit, run-in period and baseline assessments, the eligible subjects entered the treatment period and were randomized in a 3:2 ratio to one of the two treatment groups:\n\n* 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.\n* Matching placebo + standard of care treatment. After completion of the last dose on Day 85 of treatment period, subjects returned for the final efficacy assessment on Day 92. Following the treatment period, all subjects entered a 13-week safety follow-up period, including the End of Study (EoS) visit on Day 176."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, allergic, eosinophilic, non-T2 high, allergy triggered asthma, reactive asthma, asthma attack, difficulty breathing"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 118, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "CJM112", "type": "EXPERIMENTAL", "description": "Study treatment", "interventionNames": ["Drug: CJM112"]}, {"label": "Placebo to CJM112", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Other: Placebo to CJM112"]}], "interventions": [{"type": "DRUG", "name": "CJM112", "description": "300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.", "armGroupLabels": ["CJM112"]}, {"type": "OTHER", "name": "Placebo to CJM112", "description": "Placebo to match CJM112 + standard of care treatment", "armGroupLabels": ["Placebo to CJM112"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume in One Second (FEV1)", "description": "The primary efficacy analysis assessed the effect of CJM112 on the absolute change from baseline in trough FEV1 in Liters compared to placebo on Day 92. Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline measurement was defined as the baseline visit pre-bronchodilator spirometry assessment.", "timeFrame": "Baseline, Day 92"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume 1 (FEV1) % of Predicted", "description": "The secondary efficacy analyses assessed the effect of CJM112 on the absolute change from baseline in trough FEV1 in % of predicted compared to placebo on Day 92. Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. FEV1% of predicted is defined as FEV1% of the patient divided by the average FEV1% in the population for any person of similar age, sex and body composition. Pre-bronchodilator FEV1% of predicted was directly provided as part of the spirometry assessment.", "timeFrame": "Baseline, Day 92"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 6 (ACQ6) Score", "description": "The ACQ-6 is a validated asthma assessment tool that consists of 6 self-assessment questions. Each item on the ACQ-6 has a possible score ranging from 0 to 6 and the total score is the mean of all responses. The seven-point response scale goes from 0 = 'totally controlled' to 6 = 'severely uncontrolled.\n\nNegative change from baseline values indicate improved asthma control.", "timeFrame": "Baseline, Day 92"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 7 (ACQ7) Score", "description": "The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.", "timeFrame": "Baseline, Day 92"}, {"measure": "Percentage of Patients With at Least 0.5 Decrease in ACQ7 Score", "description": "The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.\n\nAn ACQ7 responder is defined as a patient with a decrease in score of greater or equal to 0.5 when compared to baseline.", "timeFrame": "Baseline, Day 92"}, {"measure": "Percentage of Patients With Adverse Events (AEs) Leading to Discontinuation of Study Treatment", "description": "Number of patients with at least one adverse event leading to discontinuation of study treatment", "timeFrame": "85 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with a physician-diagnosed history of moderate to severe asthma for a period of at least one year prior to screening.\n2. Patients on a stable therapy regimen of asthma for at least 3 months prior to screening with at least medium dose inhaled glucocorticoid and at least one additional asthma controller medication (such as inhaled long-acting bronchodilator, leukotriene antagonist, theophylline, stable low dose glucocorticoid, etc).\n3. Acceptable and reproducible spirometry with FEV1 \u2265 40 and \u2264 90% of predicted at screening and baseline (re-testing is allowed once).\n4. ACQ score \u2265 1.5 at screening and baseline (re-testing is allowed once).\n5. Total serum IgE \\< 150 IU/mL\n6. Peripheral blood eosinophils \\<300/\u03bcL\n\nExclusion Criteria:\n\n1. Previous use of biologics or other concomitant medications within the time periods specified in the SOM/protocol.\n2. History of ongoing, chronic, or recurrent moderate or severe infectious disease.\n3. Patients who have smoked or inhaled nicotine or tobacco products within the 6 month period prior to Visit 1 or who have a smoking history of greater than 10 pack years.\n4. Patients who have had an asthma attack/exacerbation requiring systemic corticosteroids for at least 3 continuous days within 4 weeks prior to screening.\n5. Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to Visit 1 or during the screening period.\n6. Women of child-bearing potential unless they use highly effective methods of contraception during dosing and for 13 weeks after stopping of investigational drug.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "Novartis Investigative Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Novartis Investigative Site", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Novartis Investigative Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Novartis Investigative Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Novartis Investigative Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "state": "Rosario", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Jette", "state": "Brussel", "zip": "1090", "country": "Belgium", "geoPoint": {"lat": 50.87309, "lon": 4.33419}}, {"facility": "Novartis Investigative Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Novartis Investigative Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Novartis Investigative Site", "city": "Aalborg", "zip": "DK 9000", "country": "Denmark", "geoPoint": {"lat": 57.048, "lon": 9.9187}}, {"facility": "Novartis Investigative Site", "city": "Copenhagen NV", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Novartis Investigative Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Novartis Investigative Site", "city": "Odense C", "zip": "DK 5000", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "Novartis Investigative Site", "city": "Montpellier cedex 5", "state": "Herault", "zip": "34059", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novartis Investigative Site", "city": "Lyon Cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12159", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Grosshansdorf", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Jerusalem", "zip": "91120", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigative Site", "city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigative Site", "city": "Rehovot", "zip": "76100", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Novartis Investigative Site", "city": "Levice", "zip": "034 01", "country": "Slovakia", "geoPoint": {"lat": 48.21563, "lon": 18.60705}}, {"facility": "Novartis Investigative Site", "city": "Spisska Nova Ves", "zip": "052 01", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicaltrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=599"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "After an initial screening visit, run-in period and baseline assessments, the eligible subjects entered the treatment period and were randomized in a 3:2 ratio to one of the two treatment groups.", "recruitmentDetails": "Participants were from Argentina (2), Belgium (3), Germany (5), Denmark (4), France (2), Israel (3), Slovakia (2), The United States (7)", "groups": [{"id": "FG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "FG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "periods": [{"title": "Treatment Epoch", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "70"}, {"groupId": "FG001", "numSubjects": "48"}]}, {"type": "PD (Pharmacodynamics) Analysis Set", "comment": "All subjects with available PD data, who received any study drug, and no major protocol deviations", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "48"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Subject/Guardian Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}]}]}, {"title": "Follow-up Epoch", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "43"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Subject/Guardian Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "BG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "118"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.1", "spread": "12.79"}, {"groupId": "BG001", "value": "55.9", "spread": "11.62"}, {"groupId": "BG002", "value": "56.6", "spread": "12.29"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "71"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "47"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "108"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Forced Expiratory Volume in One Second (FEV1)", "description": "The primary efficacy analysis assessed the effect of CJM112 on the absolute change from baseline in trough FEV1 in Liters compared to placebo on Day 92. Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline measurement was defined as the baseline visit pre-bronchodilator spirometry assessment.", "populationDescription": "The analysis population included the Pharmacodynamics (PD) analysis set with evaluable FEV1 data at both timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline, Day 92", "groups": [{"id": "OG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.043", "spread": "0.031"}, {"groupId": "OG001", "value": "0.016", "spread": "0.030"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.7374", "pValueComment": "Probability CJM112 better than placebo", "statisticalMethod": "Bayesian linear repeated measures model", "paramType": "Mean Difference (Net)", "paramValue": "0.027", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.029", "ciUpperLimit": "0.082", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.043", "otherAnalysisDescription": "Lower limit and upper limit represents the Credibility Interval from the Bayesian analysis."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume 1 (FEV1) % of Predicted", "description": "The secondary efficacy analyses assessed the effect of CJM112 on the absolute change from baseline in trough FEV1 in % of predicted compared to placebo on Day 92. Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. FEV1% of predicted is defined as FEV1% of the patient divided by the average FEV1% in the population for any person of similar age, sex and body composition. Pre-bronchodilator FEV1% of predicted was directly provided as part of the spirometry assessment.", "populationDescription": "The analysis population included the Pharmacodynamics (PD) analysis set with evaluable FEV1 data at both timepoints", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent predicted", "timeFrame": "Baseline, Day 92", "groups": [{"id": "OG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.064", "spread": "0.914"}, {"groupId": "OG001", "value": "0.151", "spread": "1.105"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.263", "pValueComment": "1-sided p-value; p-value smaller than 0.1 is considered as statistically significant", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.913", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.939", "ciUpperLimit": "2.766", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.434"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire 6 (ACQ6) Score", "description": "The ACQ-6 is a validated asthma assessment tool that consists of 6 self-assessment questions. Each item on the ACQ-6 has a possible score ranging from 0 to 6 and the total score is the mean of all responses. The seven-point response scale goes from 0 = 'totally controlled' to 6 = 'severely uncontrolled.\n\nNegative change from baseline values indicate improved asthma control.", "populationDescription": "The analysis population included the Pharmacodynamics (PD) analysis set with evaluable ACQ6 data at both timepoints", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on scale", "timeFrame": "Baseline, Day 92", "groups": [{"id": "OG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.93", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.061", "pValueComment": "1-sided p-value; p-value smaller than 0.1 is considered as statistically significant", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.22", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.41", "ciUpperLimit": "-0.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.14"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire 7 (ACQ7) Score", "description": "The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.", "populationDescription": "The analysis population included the Pharmacodynamics (PD) analysis set with evaluable ACQ7 data at both timepoints", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on scale", "timeFrame": "Baseline, Day 92", "groups": [{"id": "OG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.60", "spread": "0.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.040", "pValueComment": "1-sided p-value; p-value smaller than 0.1 is considered as statistically significant", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.23", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.40", "ciUpperLimit": "-0.06", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.13"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With at Least 0.5 Decrease in ACQ7 Score", "description": "The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.\n\nAn ACQ7 responder is defined as a patient with a decrease in score of greater or equal to 0.5 when compared to baseline.", "populationDescription": "The analysis population included the Pharmacodynamics (PD) analysis set with evaluable ACQ7 data at both timepoints", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline, Day 92", "groups": [{"id": "OG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "19"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Adverse Events (AEs) Leading to Discontinuation of Study Treatment", "description": "Number of patients with at least one adverse event leading to discontinuation of study treatment", "populationDescription": "Safety analysis set: Subjects who received any study drug", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "85 days", "groups": [{"id": "OG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Adverse events were collected from first dose of study treatment until end of study treatment plus 91 days post treatment, up to maximum duration of 6 months", "description": "Any sign or symptom that occurs during the study treatment plus the 91 days post treatment", "eventGroups": [{"id": "EG000", "title": "CJM112 300 mg", "description": "Study treatment: 300 mg CJM112 s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12", "deathsNumAffected": 0, "deathsNumAtRisk": 70, "seriousNumAffected": 3, "seriousNumAtRisk": 70, "otherNumAffected": 55, "otherNumAtRisk": 70}, {"id": "EG001", "title": "Placebo", "description": "Placebo to CJM112: Placebo s.c. injection received once per week for the first 4 weeks, followed by once every two weeks up to Week 12", "deathsNumAffected": 0, "deathsNumAtRisk": 48, "seriousNumAffected": 2, "seriousNumAtRisk": 48, "otherNumAffected": 38, "otherNumAtRisk": 48}], "seriousEvents": [{"term": "Stress cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}], "otherEvents": [{"term": "Arrhythmia supraventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 48}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Proctalgia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 48}]}, {"term": "Injection site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 48}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 48}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Arthropod sting", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Subcutaneous haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Amylase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood alkaline phosphatase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood bicarbonate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood cholesterol increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood lactate dehydrogenase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Blood triglycerides increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Lipase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Protein urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Red blood cell sedimentation rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 48}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Limb discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 48}]}, {"term": "Intercostal neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Prostatitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 48}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 48}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 48}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 48}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "Novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-05-15", "uploadDate": "2020-07-03T03:49", "filename": "Prot_001.pdf", "size": 502005}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-08-14", "uploadDate": "2020-07-03T03:49", "filename": "SAP_000.pdf", "size": 257745}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2020-07-17", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M7591", "name": "Dyspnea", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}